Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 7 art units • 8 examiners • 0 of 9 (0%) have an AI response strategy ready • 18 patents granted in the last 365 days
Shionogi & Co., Ltd. has 10 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 9 examiners across 7 art units, indicating broad examiner distribution within a defined set of technical groups.
CHAO, ALLEN is the busiest examiner, with 2 pending matters. Counsel can coordinate that small group while organizing the remaining matters by application and art unit.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (11%) |
| §103 only | 1 (11%) |
| §112 only | 1 (11%) |
| Double-patenting only | 1 (11%) |
| Double-patenting + other | 1 (11%) |
| Multi-statute (no §101) | 3 (33%) |
| No statute on record | 1 (11%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHAO, ALLEN | 2 | 60.0% | +0.0% |
| TORRICO-LOPEZ, ALAN | 1 | 29.3% | +37.3% |
| KOSAR, ANDREW D | 1 | 41.9% | +31.9% |
| MOORE, SUSANNA | 1 | 68.0% | +31.6% |
| GONZALEZ, LUISALBERTO | 1 | 59.7% | +46.3% |
| ALLEN, MICHAEL D | 1 | 31.9% | +48.8% |
| FAY, ZOHREH ALEMZADEH | 1 | 52.1% | -6.2% |
| KAUFMAN, CLAIRE M | 1 | 63.3% | +51.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278876 | METHOD FOR DETECTING AND QUANTIFYING NUCLEIC ACID FROM ENVIRONMENTAL SAMPLES | ALLEN, MICHAEL D | 2d overdue |
| 18014097 | COMBINED USE OF ANTI-CCR8 ANTIBODY AND CHEMOTHERAPEUTIC AGENT | KAUFMAN, CLAIRE M | 30d |
| 19471925 | PREDICTION SYSTEM, PREDICTION METHOD, AND PROGRAM | TORRICO-LOPEZ, ALAN | — |
| 18711747 | COVID-19 TREATMENT MEDICINE CHARACTERIZED BY COMBINING 3CL PROTEASE INHIBITOR AND COVID-19 TREATMENT DRUG | GONZALEZ, LUISALBERTO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278876 | METHOD FOR DETECTING AND QUANTIFYING NUCLEIC ACID FROM ENVIRONMENTAL SAMPLES | ALLEN, MICHAEL D | 2d overdue |
| 18014097 | COMBINED USE OF ANTI-CCR8 ANTIBODY AND CHEMOTHERAPEUTIC AGENT | KAUFMAN, CLAIRE M | 30d |
| 18578932 | NITROGEN-CONTAINING TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | KOSAR, ANDREW D | 84d |
| 19471925 | PREDICTION SYSTEM, PREDICTION METHOD, AND PROGRAM | TORRICO-LOPEZ, ALAN | — |
| 18755191 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | MOORE, SUSANNA | — |
| 18711747 | COVID-19 TREATMENT MEDICINE CHARACTERIZED BY COMBINING 3CL PROTEASE INHIBITOR AND COVID-19 TREATMENT DRUG | GONZALEZ, LUISALBERTO | — |
| Art Unit | Apps |
|---|---|
| 1622 | 2 |
| 1624 | 2 |
| 3625 | 1 |
| 1625 | 1 |
| 1671 | 1 |
| 1617 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19471925 | PREDICTION SYSTEM, PREDICTION METHOD, AND PROGRAM | TORRICO-LOPEZ, ALAN | 3625 | §101§102§103 | Non-Final OA | — | Pending | Oct 02, 2025 |
| 18891180 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | CHAO, ALLEN | 1622 | DP | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18578932 | NITROGEN-CONTAINING TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | KOSAR, ANDREW D | 1625 | — | Final Rejection | 84d | Pending | Aug 22, 2024 |
| 18755191 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | MOORE, SUSANNA | 1624 | §112DP | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18711747 | COVID-19 TREATMENT MEDICINE CHARACTERIZED BY COMBINING 3CL PROTEASE INHIBITOR AND COVID-19 TREATMENT DRUG | GONZALEZ, LUISALBERTO | 1624 | §102§112 | Non-Final OA | — | Pending | May 20, 2024 |
| 18278876 | METHOD FOR DETECTING AND QUANTIFYING NUCLEIC ACID FROM ENVIRONMENTAL SAMPLES | ALLEN, MICHAEL D | 1671 | §102§103§112 | Non-Final OA | 2d overdue | Pending | Aug 25, 2023 |
| 18335687 | DIHYDROOXADIAZINONE COMPOUND AND PHARMACEUTICAL USE THEREOF | CHAO, ALLEN | 1622 | §112 | Final Rejection | 9d | Pending | Jun 15, 2023 |
| 18007119 | LYOPHILIZED FORMULATION CONTAINING CEPHALOSPORIN HAVING CATECHOL GROUP AND THE MANUFACTURING METHOD | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | 27d | Pending | Jan 27, 2023 |
| 18014097 | COMBINED USE OF ANTI-CCR8 ANTIBODY AND CHEMOTHERAPEUTIC AGENT | KAUFMAN, CLAIRE M | 1674 | §102§112Other | Non-Final OA | 30d | Pending | Dec 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShionogi & Co., Ltd. has 9 pending office actions as of October 2026, spread across 7 art units and 8 examiners.
Allen Chao has the most, with 2 of Shionogi & Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
